File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Histologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-α therapy

TitleHistologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-α therapy
Authors
Issue Date1992
PublisherAmerican Society for Clinical Pathology. The Journal's web site is located at http://www.ajcp.com
Citation
American Journal Of Clinical Pathology, 1992, v. 98 n. 4, p. 402-407 How to Cite?
AbstractTo evaluate the histologic effects of interferon-α (IFNα) therapy on chronic hepatitis B virus (HBV) infection, a semiquantitative study using a modified Knodell's numeric histologic scoring system was performed on paired pre- and post-treatment liver biopsy specimens from 127 adult Chinese patients from two trials of IFNα therapy (IFNα, n = 86; control, n = 41). The effects of IFNα therapy on the hepatic expression of HBV antigens were also determined using immunohistochemical analysis. Serologic response with clearance of HBV e antigen (n = 18) was associated with reduction in lobular activity, periportal piecemeal necrosis, portal inflammation, and total histologic scores. Loss of HBV e antigen also was associated with a reduction in the amount of HBV core antigen in the hepatocytes. In contrast, there was an increase in hepatic expression of HBV surface antigen after IFNα therapy. Patients who lost HBV e antigen with IFNα therapy were characterized by more severe initial periportal piecemeal necrosis before treatment. These data indicate that (1) serologic response is associated with a reduction in hepatic HBV replication and an improvement in hepatic histology, and (2) patients with severe periportal piecemeal necrosis respond more favorably to IFNα therapy.
Persistent Identifierhttp://hdl.handle.net/10722/161948
ISSN
2015 Impact Factor: 2.278
2015 SCImago Journal Rankings: 1.129
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWu, PCen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLau, JYNen_US
dc.contributor.authorLauder, IJen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:16:14Z-
dc.date.available2012-09-05T05:16:14Z-
dc.date.issued1992en_US
dc.identifier.citationAmerican Journal Of Clinical Pathology, 1992, v. 98 n. 4, p. 402-407en_US
dc.identifier.issn0002-9173en_US
dc.identifier.urihttp://hdl.handle.net/10722/161948-
dc.description.abstractTo evaluate the histologic effects of interferon-α (IFNα) therapy on chronic hepatitis B virus (HBV) infection, a semiquantitative study using a modified Knodell's numeric histologic scoring system was performed on paired pre- and post-treatment liver biopsy specimens from 127 adult Chinese patients from two trials of IFNα therapy (IFNα, n = 86; control, n = 41). The effects of IFNα therapy on the hepatic expression of HBV antigens were also determined using immunohistochemical analysis. Serologic response with clearance of HBV e antigen (n = 18) was associated with reduction in lobular activity, periportal piecemeal necrosis, portal inflammation, and total histologic scores. Loss of HBV e antigen also was associated with a reduction in the amount of HBV core antigen in the hepatocytes. In contrast, there was an increase in hepatic expression of HBV surface antigen after IFNα therapy. Patients who lost HBV e antigen with IFNα therapy were characterized by more severe initial periportal piecemeal necrosis before treatment. These data indicate that (1) serologic response is associated with a reduction in hepatic HBV replication and an improvement in hepatic histology, and (2) patients with severe periportal piecemeal necrosis respond more favorably to IFNα therapy.en_US
dc.languageengen_US
dc.publisherAmerican Society for Clinical Pathology. The Journal's web site is located at http://www.ajcp.comen_US
dc.relation.ispartofAmerican Journal of Clinical Pathologyen_US
dc.subject.meshAntigens, Viral - Blooden_US
dc.subject.meshBiopsyen_US
dc.subject.meshBlotting, Southernen_US
dc.subject.meshChina - Epidemiologyen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_US
dc.subject.meshHepatitis B - Drug Therapy - Epidemiology - Pathologyen_US
dc.subject.meshHepatitis B Antibodies - Analysisen_US
dc.subject.meshHepatitis B Core Antigens - Analysisen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHepatitis B E Antigens - Analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshInterferon-Alpha - Therapeutic Useen_US
dc.subject.meshLiver - Drug Effects - Pathologyen_US
dc.subject.meshNecrosisen_US
dc.titleHistologic changes in Chinese patients with chronic hepatitis B virus infection after interferon-α therapyen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1415022-
dc.identifier.scopuseid_2-s2.0-0026725825en_US
dc.identifier.volume98en_US
dc.identifier.issue4en_US
dc.identifier.spage402en_US
dc.identifier.epage407en_US
dc.identifier.isiWOS:A1992JU01800005-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLau, JYN=7402446047en_US
dc.identifier.scopusauthoridLauder, IJ=35564928000en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats